Overview

Multiple Ascending Dose Study of HU6 in High BMI Volunteers

Status:
Completed
Trial end date:
2021-07-30
Target enrollment:
Participant gender:
Summary
This is a 14-day multiple ascending dose trial in high BMI volunteers in up to 4 cohorts of 10 high BMI volunteers each consisting of 8 receiving HU6 and 2 receiving placebo. Upon review of the safety and PK data, it may be decided to expand the current cohort size and/or dose escalate to the next cohort. In addition, the sponsor may elect not to enroll all 4 cohorts based on safety and/or PK and/or PD data, or enlist an additional cohort at a higher dose if deemed safe.
Phase:
Phase 1
Details
Lead Sponsor:
Rivus Pharmaceuticals, Inc.